Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates.
Latest Ratings for GILD
DateFirmActionFromTo Mar 2022BarclaysMaintainsUnderweight Mar 2022RBC CapitalMaintainsOutperform Feb 2022BMO CapitalDowngradesOutperformMarket Perform